Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
暂无分享,去创建一个
A. Zelenetz | I. Flinn | B. Coiffier | A. Pettitt | B. Cheson | T. Kipps | M. Hallek | S. Stilgenbauer | S. O'brien | T. Jahn | J. Pagel | L. Miller | S. Coutre | R. Furman | P. Ghia | T. Ervin | P. Cramer | J. Sharman | P. Hillmen | H. Eradat | N. Lamanna | J. Barrientos | D. Johnson | R. Dansey | Daniel Li | Maria Aiello | S. Ma | Shuo Ma
[1] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[2] J. Leonard,et al. Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. , 2013 .
[3] J. Byrd,et al. Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. , 2013 .
[4] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[5] J. Byrd,et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[7] M. Keating,et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.
[8] J. Gribben,et al. Update on therapy of chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Ulrich,et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.
[10] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[11] H. Döhner,et al. TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Jeffrey A Jones,et al. Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .
[13] M. Dyer,et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Byrd,et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] ONSTANZE,et al. GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .
[16] M. Hallek,et al. Treatment of elderly patients with chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.
[17] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[18] F. Buccisano,et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. , 2008, Blood.
[19] N. Chiorazzi,et al. mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .
[20] K. Okkenhaug,et al. PI3K in lymphocyte development, differentiation and activation , 2003, Nature Reviews Immunology.
[21] Arthur Weiss,et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.
[22] E. Kimby,et al. Standard‐dose anti‐CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study , 2002, European journal of haematology.
[23] Axel Benner,et al. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.
[24] E. Cesarman,et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. , 2001, Blood.
[25] D. Huhn,et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. , 2001, Blood.
[26] M. Grever,et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Kantarjian,et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] E. Schattner,et al. Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells1 , 2000, The Journal of Immunology.
[29] E. Schattner,et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. , 2000, Journal of immunology.
[30] T. Kipps,et al. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. , 1999, Blood.
[31] G. Lyman,et al. Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.